Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
Saucony® Unveils Saucony SILO: A New Pinnacle in Luxury Footwear
10:00am, Thursday, 17'th Apr 2025
The SS25 collection will be available globally on April 17 NEW YORK , April 17, 2025 /PRNewswire/ -- Saucony, a global performance running and lifestyle brand, today revealed the details behind Saucon
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
08:40am, Wednesday, 26'th Mar 2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
01:30pm, Wednesday, 26'th Feb 2025
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dr
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
08:50am, Tuesday, 18'th Feb 2025
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or t
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
07:45am, Tuesday, 11'th Feb 2025
No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or t
LIBERTY LATIN AMERICA'S C&W CREDIT SILO COMPLETES REFINANCING PROGRAM; ISSUES NEW $755 MILLION SENIOR NOTES DUE 2033
05:49pm, Monday, 10'th Feb 2025
DENVER, Colorado--(BUSINESS WIRE)--Liberty Latin America's (“LLA” or the “Company”) largest credit silo, Cable & Wireless (“C&W”), has priced new $755 million senior notes due 2033 with a
LIBERTY LATIN AMERICA'S C&W CREDIT SILO PRICES NEW $1.5 BILLION TERM LOAN DUE 2032
04:31pm, Tuesday, 04'th Feb 2025
DENVER, Colorado--(BUSINESS WIRE)--Liberty Latin America's (“LLA” or the “Company”) largest credit silo, Cable & Wireless (“C&W”), priced a new $1.5 billion term loan at the end of January
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
08:29am, Wednesday, 22'nd Jan 2025
SARASOTA, FL, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and dr
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
08:45am, Thursday, 02'nd Jan 2025
SARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” “we,” “us,” “our,” or the “Company”), a developmental stage biopharmaceutical company focus
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia
07:35am, Wednesday, 18'th Dec 2024
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”)
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
08:05am, Friday, 29'th Nov 2024
Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Compan
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
08:40am, Monday, 18'th Nov 2024
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
08:35am, Thursday, 31'st Oct 2024
The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
06:35am, Tuesday, 10'th Sep 2024
Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
02:30pm, Wednesday, 14'th Aug 2024
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SA
